ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy

ARTCLINE gibt Abschluss einer Finanzierung in Höhe von 5 Millionen Euro bekannt

100 patients already enrolled: ARTCLINE reports rapid progress in multicenter clinical study on immune support in septic shock (ReActIF-ICE)

ARTCLINE Establishes Scientific Advisory Board with Leading Experts from Nephrology, Intensive Care and Transfusion Medicine

ARTCLINE appoints Dirk Hessel as Managing Director and Prepares the Market Entry for Innovative Septic Shock Treatment

ARTCLINE successfully completes capital increases of EUR 4.4 million

First Patients enrolled in EU randomized Trial of ARTCLINEs Immune-cell Therapy System for treatment of septic shock

ARTCLINE receives 4 million euros and starts clinical trial with novel immune cell therapy for septic shock patients

Journal “TRANSFUSION” publishes article on new cell therapy method of ARTCLINE

The Federal Ministry for Economic Affairs and Energy promotes ARTCLINE’s extracorporeal immune cell therapy